BIOV Stock Overview
Develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Bio-View Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.26 |
| 52 Week High | ₪0.37 |
| 52 Week Low | ₪0.22 |
| Beta | 0.39 |
| 1 Month Change | -10.76% |
| 3 Month Change | -11.38% |
| 1 Year Change | -7.89% |
| 3 Year Change | -25.57% |
| 5 Year Change | 10.97% |
| Change since IPO | -63.90% |
Recent News & Updates
Recent updates
Some Shareholders Feeling Restless Over Bio-View Ltd's (TLV:BIOV) P/E Ratio
Dec 19
Shareholders Will Probably Not Have Any Issues With Bio-View Ltd's (TLV:BIOV) CEO Compensation
Dec 04Estimating The Intrinsic Value Of Bio-View Ltd (TLV:BIOV)
Feb 14Does BioView Ltd.'s (TLV:BIOV) Weak Fundamentals Mean That The Market Could Correct Its Share Price?
Jan 20What BioView Ltd.'s (TLV:BIOV) 35% Share Price Gain Is Not Telling You
Nov 29
Shareholder Returns
| BIOV | IL Medical Equipment | IL Market | |
|---|---|---|---|
| 7D | -5.5% | 1.6% | 4.2% |
| 1Y | -7.9% | 18.3% | 34.1% |
Return vs Industry: BIOV underperformed the IL Medical Equipment industry which returned 16% over the past year.
Return vs Market: BIOV underperformed the IL Market which returned 33% over the past year.
Price Volatility
| BIOV volatility | |
|---|---|
| BIOV Average Weekly Movement | 8.2% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in IL Market | 8.1% |
| 10% least volatile stocks in IL Market | 3.6% |
Stable Share Price: BIOV's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: BIOV's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 33 | Daniel Klain | www.bioview.com |
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company’s products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH and Karyotype samples in real-time; and Allegro Plus, an automatic imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an automated imaging system that supports multiple applications; Encore, an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; Solo Touch Workstation, a stand-alone workstation that streamlines review and analysis of test results away from the microscope; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases.
Bio-View Ltd Fundamentals Summary
| BIOV fundamental statistics | |
|---|---|
| Market cap | ₪33.84m |
| Earnings (TTM) | -₪3.15m |
| Revenue (TTM) | ₪25.66m |
1.3x
P/S Ratio-10.7x
P/E RatioIs BIOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOV income statement (TTM) | |
|---|---|
| Revenue | ₪25.66m |
| Cost of Revenue | ₪10.09m |
| Gross Profit | ₪15.56m |
| Other Expenses | ₪18.71m |
| Earnings | -₪3.15m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 60.65% |
| Net Profit Margin | -12.27% |
| Debt/Equity Ratio | 0% |
How did BIOV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/10 00:44 |
| End of Day Share Price | 2025/05/08 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bio-View Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.